Literature DB >> 12591731

Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.

Adam Stevens1, Joanne Soden, Paul E Brenchley, Shirley Ralph, David W Ray.   

Abstract

The human vascular endothelial growth factor (VEGF) gene is unusually polymorphic,and there is evidence for inheritance of conserved haplotypes. One haplotype, carrying polymorphisms at -460/+405, is associated with enhanced production of VEGF in vitro. The VEGF promoter is activated by phorbol esters and, in endometrial cells, by estrogen. We have analyzed the impact of the common -460/+405 polymorphism on both basal and stimulated VEGF transcription using the human breast cancer cell line MCF7. Because the VEGF promoter is so highly polymorphic, haplotypes were established and analyzed. Carriage of the -460/+405 polymorphisms increased basal promoter activity by 71% compared with the wild-type sequence. However, this effect was dependent on colinearity with a series of further 5' sequence polymorphisms. The -460/+405 polymorphism also increased the mean induction by phorbol ester from 5-fold to 8.5-fold. In contrast to earlier studies in endometrial cells, none of the human VEGF promoter constructs was regulated by estrogen. Overexpression of the estrogen receptor did not confer estrogen regulation to VEGF, implying cell type-specific hormonal regulation. Therefore, carriage of the -460/+405 polymorphism significantly alters VEGF promoter activity and responsiveness. This has implications for the inherited susceptibility of common diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591731

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  102 in total

Review 1.  Bevacizumab.

Authors:  Filis Kazazi-Hyseni; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2010-08-05

2.  Meta analysis on the relationship between gene polymorphisms of vascular endothelial growth factor and retinal prognosis risk of prematurity.

Authors:  Jun Zhai; Qiu-Hui Jiang; Chun-Xi Liu; Zuo-Rong Tian; Ying-Pu Sun
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

3.  Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.

Authors:  Vincenzo Formica; Raffaele Palmirotta; Girolamo Del Monte; Annalisa Savonarola; Giorgia Ludovici; Maria Laura De Marchis; Italia Grenga; Michele Schirru; Fiorella Guadagni; Mario Roselli
Journal:  Int J Colorectal Dis       Date:  2010-12-29       Impact factor: 2.571

4.  Novel functional single nucleotide polymorphisms in the latent transforming growth factor-beta binding protein-1L promoter: effect on latent transforming growth factor-beta binding protein-1L expression level and possible prognostic significance in ovarian cancer.

Authors:  Tomomi Higashi; Satoru Kyo; Masaki Inoue; Hideji Tanii; Kiyofumi Saijoh
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

5.  VEGF +936C/T and +460C/T gene polymorphisms and oral cancer risk: a meta-analysis.

Authors:  Su-Feng Zhao; Ping Zhan; Xu-Dong Yang; Ming-Xing Lu; Guo-Wen Sun; Yu-Xin Wang; Yin-Kai Zhang; Yu-Mei Pu; En-Yi Tang
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

6.  VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population.

Authors:  Melissa D Amosco; Van Anthony M Villar; Justin Michael A Naniong; Lara Marie G David-Bustamante; Pedro A Jose; Cynthia P Palmes-Saloma
Journal:  Clin Exp Hypertens       Date:  2016-09-26       Impact factor: 1.749

7.  Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.

Authors:  Fernando Cruz-Gonzalez; Lucía Cabrillo-Estévez; Gloria López-Valverde; Clara Cieza-Borrella; Emiliano Hernández-Galilea; Rogelio González-Sarmiento
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-13       Impact factor: 3.117

8.  Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy.

Authors:  T Langsenlehner; E-M Thurner; W Renner; A Gerger; K S Kapp; U Langsenlehner
Journal:  Strahlenther Onkol       Date:  2014-01-18       Impact factor: 3.621

9.  Association of vascular endothelial growth factor C-634 g polymorphism in taiwanese children with Kawasaki disease.

Authors:  K-C Hsueh; Y-J Lin; J-S Chang; L Wan; Y-H Tsai; C-H Tsai; C-P Chen; F-J Tsai
Journal:  Pediatr Cardiol       Date:  2007-09-15       Impact factor: 1.655

10.  Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.

Authors:  Hayra de Andrade Vieira-Monteiro; Daniely Regina Freitas-Alves; Marcelo Sobral-Leite; João Marcos de Azevedo Delou; Sheyla Maria Torres Goulart-Citrangulo; Camila Telles do Nascimento; Thales Nascimento E Castro; Sérgio Koifman; Jamila Alessandra Perini; Rosane Vianna-Jorge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.